Quince Therapeutics, Inc. reports an amendment to its unsecured credit facility with the European Investment Bank. For the period from January 1, 2026 to March 31, 2026, the company’s required minimum cash balance under the EIB Facility will be reduced from EUR 14,650,000 to EUR 5,000,000, temporarily easing its cash covenant. During this same period, out of the overall 9% Deferred Interest Rate on Tranche A and Tranche B, 1% will be converted into a Fixed Rate to be paid on March 31, 2026 on those tranches. The full amendment will be filed as an exhibit to the company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
Quince Therapeutics, Inc. Schedule 13G filed by Nantahala Capital Management, LLC and two individuals reports collective beneficial ownership of 4,765,862 shares, representing 9.99% of outstanding common stock as of June 30, 2025. The reported holdings include 2,237,562 shares that the reporting persons may acquire within 60 days through the exercise of warrants. Nantahala and principals Wilmot B. Harkey and Daniel Mack report no sole voting or dispositive power but share voting and dispositive power over all reported shares. Blackwell Partners LLC - Series A, a fund advised by Nantahala, is identified as having rights to dividends or sale proceeds on more than 5% of the shares reported.
Quince Therapeutics is a late-stage biotech developing the AIDE red blood cell encapsulation platform and a Phase 3 lead asset, eDSP, targeting Ataxia-Telangiectasia. The company reported consolidated assets of $117.2 million, liabilities of $105.5 million, and stockholders' equity of $11.7 million as of June 30, 2025. Cash, cash equivalents and short-term investments totaled $34.7 million, while the accumulated deficit was $407.6 million.
Operating results show a continuing loss: $16.0 million net loss for the quarter and $31.1 million for the six months ended June 30, 2025, driven by higher R&D spending ($14.7 million for six months) and other non-cash fair value adjustments. The balance sheet includes €10.0 million ($11.7M) outstanding on an EIB loan, contingent consideration of $59.1 million, and warrant liabilities of $15.1 million. Management concluded that substantial doubt exists about the company’s ability to continue as a going concern within one year and notes the need for additional financing despite recent capital raises totaling approximately $14.4 million from a June 2025 private placement and ATM activity.
Quince Therapeutics, Inc. reported that on August 11, 2025 it announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. The company states the related press release is furnished as Exhibit 99.1 to this Current Report. The filing explicitly says the information (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No financial figures or business-detail text from the press release are included in the provided document. The report is signed by Dirk Thye, Chief Executive Officer and Chief Medical Officer.
Quince Therapeutics (Nasdaq: QNCX) has filed a Form S-3 shelf registration to permit the resale of up to 17,343,856 common shares held by prior private-placement investors. The shares comprise:
- 6,671,928 outstanding common shares
- 2,000,000 shares issuable upon exercise of $0.001 pre-funded warrants
- 8,671,928 shares issuable upon exercise of $1.20 five-year common warrants
The filing adds no new capital but removes trading restrictions for the selling stockholders, who may dispose of shares at market or negotiated prices. Total potential dilution equals ~17.3 million shares, or ~32% of the 53.6 million shares outstanding as of 30 Jun 2025.
Quince is a late-stage biotech developing the AIDE red-blood-cell drug-delivery platform. Lead candidate eDSP is entering a Phase 3 NEAT trial for Ataxia-Telangiectasia, a >$1 billion addressable market with no approved therapies. The company’s common stock last closed at $1.86 (24 Jul 2025). Key risks highlighted include lack of approved products, need for additional funding, regulatory uncertainties, going-concern language in recent audit, and potential Nasdaq compliance issues.
Quince Therapeutics, Inc. (QNCX) – Form 4 insider transaction
Chief Business, Operations and Commercial Officer Brendan Hannah reported a purchase of company securities on 18 June 2025.
- Common shares acquired: 37,736 shares
- Purchase price: $1.20 per share
- Post-transaction direct ownership: 334,276 common shares
- Derivative securities acquired: 37,736 warrants with a $1.20 exercise price, expiring 18 June 2030; cost recorded at $0.125 per warrant
The filing indicates a straightforward insider purchase (Transaction Code “A”) rather than a sale or option exercise. No other changes to ownership structure or additional transactions were disclosed.
Materiality assessment: The transaction increases Hannah’s direct equity stake by approximately 11 % (37,736 ÷ 334,276 ≈ 11 %), but the absolute dollar value is relatively modest (≈ $45,000 for the shares, ≈ $4,700 for the warrants). There is no indication of broader strategic developments, earnings information, or company-level financial impact within this filing.
Quince Therapeutics (NASDAQ:QNCX) filed a Form 4 on June 28 2025 reporting that President Charles S. Ryan executed an insider purchase on June 18 2025.
Ryan bought 7,548 common shares at $1.20 each and simultaneously acquired 7,548 warrants with the same $1.20 exercise price, expiring 06/18/2030. His direct ownership rose to 130,009 common shares, an increase of roughly 5.8 %. No other material transactions or disclosures were included in the filing.
Quince Therapeutics (QNCX) filed a Form 4 disclosing that CEO, CMO and Director Dirk Thye increased his equity stake on 18 June 2025.
Thye acquired 150,944 common shares at $1.20 (Transaction Code A) and simultaneously received warrants for an additional 150,944 shares with the same $1.20 exercise price, expiring 18 June 2030. Following the transactions, his direct beneficial ownership rose to 994,885 common shares, an increase of roughly 15 %. The disclosed cash outlay for the common-share purchase is approximately $181 000; the warrants were priced at $0.125 each.
No shares were sold, and the filing does not indicate the use of a Rule 10b5-1 trading plan. These insider purchases may signal management confidence, though the dollar value is modest relative to typical market-moving thresholds.